2022 - - 13

MMWR Booster for: Pediatric HIV Case Identification Across 22 PEPFAR-Supported Countries During the COVID-19 Pandemic, October 2019–September 2020 / Weekly / July 15, 2022 / 71(28);894–898

Posted on March 21, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Significant Decrease in HIV Testing and Case Identification: The first months of the COVID-19 pandemic saw a 40.1% decrease in HIV testing and a 29.4% decrease in

MMWR Booster for: Vital Signs: Drug Overdose Deaths, by Selected Sociodemographic and Social Determinants of Health Characteristics — 25 States and the District of Columbia, 2019–2020 / Weekly / July 22, 2022 / 71(29);940–947

Posted on March 20, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Disproportionate Increases Among Black and AI/AN Persons: From 2019 to 2020, overdose death rates soared by 44% for Black individuals and by 39% for AI/AN individuals, compared

MMWR Booster for: Public Health Surveillance and Reporting for Human Toxoplasmosis — Six States, 2021 / Weekly / July 15, 2022 / 71(28);889–893

Posted on March 19, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Variability in Case Definitions: The report highlights the significant variation in toxoplasmosis case definitions across six states, affecting disease estimates and comparisons. Challenges in Surveillance: Identifying newly

MMWR Booster for: Symptoms of Mental Health Conditions and Suicidal Ideation Among State, Tribal, Local, and Territorial Public Health Workers — United States, March 14–25, 2022 / Weekly / July 22, 2022 / 71(29);925–930

Posted on March 18, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways High Prevalence of Mental Health Conditions: Among 26,069 surveyed STLT public health workers in 2022, notable percentages reported symptoms of depression (27.7%), anxiety (27.9%), PTSD (28.4%), and

MMWR Booster for: Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 / Weekly / July 22, 2022 / 71(29);931–939

Posted on March 17, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Vaccine Effectiveness (VE) varies with dose number and Omicron sublineage. VE was generally lower during the Omicron BA.2/BA.2.12.1 period compared to the BA.1 period. A third dose

MMWR Booster for: User Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022 / Weekly / July 29, 2022 / 71(30);971–976

Posted on March 16, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Reduction in Adverse Reactions: Among adults aged ≥50 years, adverse reactions were less frequent following a second mRNA COVID-19 booster dose compared to the first booster dose.

MMWR Booster: Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022 / Weekly / July 29, 2022 / 71(30);971–976

Posted on March 15, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Decreased adverse reactions after second booster: Among individuals ≥50 years who received homologous mRNA COVID-19 vaccination, both injection site and systemic reactions were reported less frequently after

MMWR Booster for: Notes from the Field: Cluster of Parechovirus Central Nervous System Infections in Young Infants — Tennessee, 2022 Weekly / July 29, 2022 / 71(30);977–978

Posted on March 14, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Outbreak Identification: Between April 12 and May 24, 2022, 23 previously healthy infants aged 5 days to 3 months were admitted with human parechovirus (PeV) meningoencephalitis to

MMWR Booster for: Influenza Activity and Composition of the 2022–23 Influenza Vaccine — United States, 2021–22 Season / Weekly / July 22, 2022 / 71(29);913–919

Posted on March 13, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Low severity and unusual pattern: The 2021–22 influenza season was characterized by low severity, with activity spanning from October 2021 through mid-June 2022, showcasing two distinct waves

MMWR Booster for: Chronic Conditions Among Adults Aged 18─34 Years — United States, 2019 / Weekly / July 29, 2022 / 71(30);964–970

Posted on March 12, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways High Prevalence of Chronic Conditions: In 2019, 53.8% of young adults (18-34 years) had at least one chronic condition, and 22.3% had multiple conditions, highlighting a significant

Epidemiology, Broadly Speaking

Tag: 2022